Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers ...

Nivolumab significantly improved median RFS and DMFS compared to ipilimumab in resected stage IIIB to IIIC or IV melanoma patients. The study suggested potential benefits of morning dosing, with ...

Nivolumab shows lasting melanoma recurrence prevention, with long-term safety, in largest-ever CheckMate 238 trial analysis.

Ipilimumab plus nivolumab improved PFS over nivolumab alone in MSI-H/dMMR mCRC, with no new safety concerns. The combination showed higher overall response rates and a favorable safety profile ...

Bristol-Myers Squibb Company (($BMY)) announced an update on their ongoing clinical study. In a recent update, Bristol-Myers ...

Final results from the pivotal CheckMate 238 trial showed adjuvant nivolumab continues to significantly improve RFS compared with ipilimumab for patients with advanced melanoma, according to data ...

Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703 Supported in part by University of Colorado Shared Resources ...

SAN FRANCISCO -- An immunotherapy combination for advanced, highly mutated colorectal cancer (CRC) significantly slowed disease progression versus a single drug, according to a randomized study.

(UroToday.com) The 2025 ESMO annual meeting featured a kidney cancer mini oral session and a presentation by Dr. Kathryn ...

“The long-term outcomes from CheckMate 238 confirm that nivolumab is a proven adjuvant treatment for patients with melanoma at high risk for recurrence, with sustained improvement in recurrence-free ...

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo, Bristol Myers Squibb) with ipilimumab (Yervoy, Bristol Myers Squibb) for the treatment of adults and children aged 12 years ...